Clinical course of 161 untreated and tenofovir‐treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region
- 20 July 2015
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 23 (1), 15-22
- https://doi.org/10.1111/jvh.12436
Abstract
Hepatitis B immunoprophylaxis failure is linked to high maternal viraemia. There is limited North American data on hepatitis B outcomes in pregnancy. Pregnant hepatitis B carriers were enrolled January 2011–December 2014 and offered tenofovir in the 3rd trimester if hepatitis B virus (HBV)‐DNA was >7‐log IU/mL. Outcomes were determined in treated vs untreated patients. In total, 161 women with 169 pregnancies (one twin, 170 infants; median age 32 years), 18% (29/161) HBeAg+ and median HBV‐DNA 2.51 log IU/mL (IQR 1.66–3.65; range 0.8–8.1) were studied. 14.3% (23/161) received tenofovir due to high viral load (16/23, median 74 days, IQR 59–110) or due to liver disease (7/23). In 10/16 treated due to high viraemia, with confirmed adherence, follow‐up HBV‐DNA showed a 5.49 log decline (P = 0.003). In treatment naïve mothers, median alanine aminotransferase (ALT) increased from 17 IU/L (IQR 12–24) to 29 (IQR 18–36) post‐partum (P = 1.5e‐7). In seven highly viraemic mothers who declined therapy (HBV‐DNA >8‐log IU/mL); median ALT increased ~3X from baseline (P < 0.01). 26% (44/169) had Caesarean section with no difference in treated vs untreated subjects. No tenofovir‐treated mothers had renal dysfunction. Data were available on 167/170 infants; in 50.8% (85/167) who completed immunoprophylaxis, 98.8% (84/85, including 12 exposed to tenofovir in utero) were HBV immune. One infant born to an HBeAg+ mother with HBV‐DNA >8‐log IU/mL failed immunoprophylaxis. In this prospective Canadian cohort study, most untreated mothers experienced mild HBV flares. Tenofovir in pregnancy is well tolerated and reduces viral load prior to parturition.Keywords
Funding Information
- Canadian Institutes of Health Research
This publication has 33 references indexed in Scilit:
- Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancyJournal of Viral Hepatitis, 2012
- New Intrauterine Growth Curves Based on United States DataPEDIATRICS, 2010
- Chronic hepatitis B: Update 2009Journal of Hepatology, 2009
- Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled studyJournal of Viral Hepatitis, 2009
- The global impact of vaccination against hepatitis B: A historical overviewVaccine, 2008
- Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virusEuropean Journal of Pediatrics, 2006
- Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infectionJournal of Viral Hepatitis, 2003
- Immunological Tolerance of the Human FetusAmerican Journal of Perinatology, 2001
- Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapyJournal of Hepatology, 1998
- Acute Hepatitis B Virus Infection: Relation of Age to the Clinical Expression of Disease and Subsequent Development of the Carrier StateThe Journal of Infectious Diseases, 1985